中医药研究论丛

233.2 中药治疗中风後失智症的疗效评估:一项回溯性世代研究
TJ TCM.23(3) : 17-34, 2020
中药治疗中风後失智症的疗效评估:一项回溯性世代研究
The Therapeutic Assessment of Chinese Herbal Medicine on Post-Stroke Dementia:
A Retrospective Cohort study 
吴佩芸1,2 廖建彰3,4,5,6,7 施纯全1,8*
义守大学医学院学士後中医学系,高雄,台湾
台北市立联合医院仁爱院区中医科,台北,台湾
台北医学大学医学院医学系麻醉科,台北,台湾
台北医学大学附设医院麻醉科,台北,台湾
台北医学大学附设医院麻醉暨卫生政策研究中心,台北,台湾
台北医学大学万芳医院大数据暨统合分析研究中心,台北,台湾
中国医药大学中医学院中医系,台中,台湾
台北医学大学中草药临床药物研发博士学位学程,台北,台湾
【摘要】
背景:中医已在亚洲盛行,也是中风患者的主要治疗方式之一。本研究目的在评估中风病患使用中药治疗是否能减少中风後失智症发生之风险。
方法:我们使用全民健康保险申报资料做为研究资料来源,本研究筛选2000-2004 年间年龄大於50 岁的初中风患者,追踪接受中药治疗组及没有接受中药治疗组两个世代至2009 年底并观察罹患中风後失智症的情形。本研究使用多变量Cox 回归模型,计算中药治疗与中风後失智症的相关危害比与95% 信赖区间。
结果:在追踪过程中,我们发现接受中药治疗的中风患者与没有接受中药治疗的中风患者相比,罹患中风後失智症的风险有显着减少(危害比=0.7095% 信赖区间=0.67-0.73)。接受中药治疗减少罹患中风後失智症风险的相关性,在不同性别、年龄、各种中风类型(出血性中风、缺血性中风、其他中风)的次族群上,都呈现统计上的显着意义。另外,我们也分析中风病患最常使用中药治疗单味药及复方的情形。
结论:本研究提出接受中药治疗可以减少中风患者罹患中风後失智症风险的可能性。建议医疗主管机关及各医院可鼓励中风患者接受中医会诊及中药治疗。本研究结果可作为医疗主管机关未来推动中风患者防治及中医药卫生政策之叁考。
【关键词】中风、失智症、中医、中药、全民健康保险
 
Pei-Yun Wu1,2Chien-Chang Liao1,3,4,5,6,7Chun-Chuan Shih1,8*   
1School of Chinese Medicine for Post-Baccalaureate, College of Medicine, I-Shou University,
Kaohsiung, Taiwan
2Department of Chinese Medicine, Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan
3Department of Anesthesiology, School of Medicine, College of Medicine, Taipei, Taiwan
4Department of Anesthesiology, Taipei Medical University Hospital, Taipei, Taiwan
5Anesthesiology and Health Policy Research Center, Taipei Medical University Hospital,
Taipei, Taiwan
6Research Center of Big Data and Meta-Analysis, Wan Fang Hospital, Taipei Medical
University, Taipei, Taiwan
7School of Chinese Medicine, College of Chinese Medicine, China Medical University,
Taichung, Taiwan
8Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy,
Taipei Medical University, Taipei, Taiwan
Summary
Background: Traditional Chinese medicine was prevalent in Asian ries and it was as one of major therapies for stroke patients. Our purpose is to evaluate the risk of dementia for stroke patients with and without use of Chinese herbal medicine (CHM).
Method: We used claim data of Taiwan’s National Health Insurance and conducted a stroke cohort study including hospitalized stroke patients aged 50 years and old in 2000-2004. Use a matching procedure by propensity score, we selected 55074 stroke patients who received CHM and 55074 stroke patients without Chinese medicine for comparison. Both cohorts were followed until the end of 2009. Multivariate Cox proportional hazard regressions were used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of incidence of dementia after stroke associated with CHM. We also analyzed the most common use of formula and herbs in stroke patients.
Results: During the follow-up period, use of CHM was associated with a decreased risk of dementia in stroke patients (HR, 0.70; 95% CI 0.67 to 0.73). The association between CHM and reduced risk of post-stroke dementia was significant in both sexes, all age group and all type of stroke. The most common used herb and formula for stroke patients were Dan Shen and Shu Jing Huo Xie Tang, respectively.
Conclusions: Our study raised the possibility that CHM is beneficial in reducing dementia risk in stroke patients. We suggested that the health authority and hospitals to encourage stroke patients receiving CHM and adjuvant therapy of traditional Chinese medicine during the stroke admission. The findings of this study is the important references for the health authority to making health policy
for stroke patients and traditional Chinese medicine.
KeywordsStroke; Dementia; Traditional Chinese Medicine; Chinese Herbal Medicine; National Health Insurance